Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
Find out how Takeda’s pediatric Entyvio review could change biologic treatment choices in ulcerative colitis and Crohn’s disease.
Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.
Early-stage biosimilar deal between Samsung Bioepis and Sandoz covers vedolizumab and four undisclosed molecules
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Can subcutaneous infliximab change how clinicians manage drug holidays in Crohn’s disease and ulcerative colitis
New ECCO 2026 data explore whether subcutaneous infliximab can reliably recapture disease control after treatment interruption. Read the analysis.
AI in clinical operations: Can PhaseV’s real-time site optimization reshape IBD trial efficiency?
Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.
MH002 enters phase 2b: Can MRM Health’s live biotherapeutic consortium redefine ulcerative colitis treatment standards?
MRM Health’s MH002 enters phase 2b for ulcerative colitis. Can this live biotherapeutic redefine immune-sparing treatment in IBD? Find out what’s at stake.
Can gut-restricted PDE4 inhibitors transform treatment for ulcerative colitis and Crohn’s?
Palisade Bio’s PALI-2108 secures a Japanese patent. Explore how this gut-targeted PDE4 inhibitor could change the game in ulcerative colitis and Crohn’s.